While there had been some risks to filgotinib’s approval cited before, analysts expressed surprise at the decision, with one writing it would likely delay approval by at least a year. Shares of both companies fell sharply on the news.
FDA issues surprise rejection of Gilead, Galapagos rheumatoid arthritis drug
